- Home
- CXM vs KROS Comparison
CXM vs KROS Comparison
Compare CXM & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXM
- KROS
- Stock Information
- Founded
- CXM 2009
- KROS 2015
- Country
- CXM United States
- KROS United States
- Employees
- CXM N/A
- KROS N/A
- Industry
- CXM Computer Software: Prepackaged Software
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CXM Technology
- KROS Health Care
- Exchange
- CXM Nasdaq
- KROS Nasdaq
- Market Cap
- CXM 2.3B
- KROS 1.8B
- IPO Year
- CXM 2021
- KROS 2020
- Fundamental
- Price
- CXM $8.92
- KROS $16.67
- Analyst Decision
- CXM Hold
- KROS Buy
- Analyst Count
- CXM 15
- KROS 11
- Target Price
- CXM $9.89
- KROS $68.83
- AVG Volume (30 Days)
- CXM 3.1M
- KROS 1.8M
- Earning Date
- CXM 12-04-2024
- KROS 11-06-2024
- Dividend Yield
- CXM N/A
- KROS N/A
- EPS Growth
- CXM 36.57
- KROS N/A
- EPS
- CXM 0.15
- KROS N/A
- Revenue
- CXM $788,062,000.00
- KROS $651,000.00
- Revenue This Year
- CXM $9.47
- KROS $224.66
- Revenue Next Year
- CXM $3.63
- KROS N/A
- P/E Ratio
- CXM $59.12
- KROS N/A
- Revenue Growth
- CXM 12.02
- KROS 8037.50
- 52 Week Low
- CXM $6.91
- KROS $15.67
- 52 Week High
- CXM $14.32
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- CXM 55.34
- KROS 22.41
- Support Level
- CXM $8.92
- KROS $16.31
- Resistance Level
- CXM $9.47
- KROS $17.64
- Average True Range (ATR)
- CXM 0.32
- KROS 2.29
- MACD
- CXM -0.06
- KROS -2.63
- Stochastic Oscillator
- CXM 37.85
- KROS 1.39
About CXM Sprinklr Inc.
Sprinklr Inc is engaged in providing enterprise software that enables every customer-facing function across the front office, from Customer Care to Marketing, to collaborate across internal silos, and communicate across digital channels. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in Americas, EMEA and other countries. It derives maximum revenue from Americas.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.